Are Supriya Lifesci. latest results good or bad?

Supriya Lifescience has reported its financial results for the quarter ending June 2025, which reflect a notable decline across several key metrics. The Profit Before Tax less Other Income (PBT) was recorded at Rs 44.74 crore, representing a decrease compared to the average of the previous four quarters. Similarly, the Profit After Tax (PAT) fell to Rs 34.79 crore, indicating a decline from prior averages.
Net sales for the quarter were reported at Rs 145.07 crore, which is the lowest figure in the past five quarters and shows a significant decline from the average of the last four quarters. The Operating Profit (PBDIT) also reached its lowest point in the same timeframe, reported at Rs 51.70 crore. Additionally, the Earnings per Share (EPS) dropped to Rs 4.32, suggesting a reduction in profitability for shareholders.

The quarterly results indicate a quarter-over-quarter decline in net sales by 21.20% and a decrease in standalone net profit by 30.94% compared to the previous quarter. The Operating Profit Margin, excluding other income, also saw a slight decline.

In light of these results, the company saw an adjustment in its evaluation. Overall, the financial data suggests that Supriya Lifescience is facing challenges in its operational performance during this reporting period.